GET DAILY SIGNALSWhy Is PepGen Inc. (PEPG) Stock Down -8.13% Today?
Key Takeaways
- PEPG dropped 8.13%, or $0.41, to $4.63 in Friday morning trading, extending a three-session pullback from its post-data peak.
- The main catalyst is the $125 million equity offering priced at $5.00 per share, which is set to settle on or about today and has left shares trading below the deal price.
- Profit-taking after Tuesday's 92.9% one-day surge is adding pressure, with the stock still roughly 28% above its pre-data close of $2.39.
- Biotech is weak across the board: the XBI biotech ETF is down 1.63% and DM1 rival DYN is off 2.06%.
- News Significance Score: 42/100 — A material dilutive financing paired with a move only modestly above the stock's typical daily swing.
- Traders are watching whether the $5.00 offering price acts as a ceiling and whether underwriters take up their 3.75 million-share option.
- Investors can review detailed Price Targets, Earnings history and forward Forecast pages for a fuller view of the setup.
- Explore Trending AI Robots to see which automated strategies are performing best in current conditions.
Opening Summary
PepGen Inc. (PEPG) is a Boston-based clinical-stage biotechnology company developing oligonucleotide therapies for rare neuromuscular diseases, led by its Enhanced Delivery Oligonucleotide platform and its lead candidate PGN-EDODM1 for myotonic dystrophy type 1. Shares were trading at $4.63 shortly before 10 a.m. ET on Friday, down 8.13% from Thursday's close of $5.04, a decline of $0.41. The direction is unambiguously lower, with the stock opening near $5.05 and sliding to an intraday low of $4.56. The immediate cause is corporate rather than clinical: a large follow-on equity offering priced at $5.00 that is wrapping up, combined with investors taking profits on a historic two-day rally.
Catalyst Breakdown: The $125 Million Offering
PepGen launched a $125 million public offering on Tuesday evening, hours after releasing its Phase 2 data, and priced it the following day at $5.00 per share for 25 million new shares — below the $5.26 close at the time. Net proceeds are estimated near $116.9 million, rising to roughly $134.5 million if underwriters exercise their full 30-day option for another 3.75 million shares. Against about 69.3 million shares outstanding before the deal, that is a share-count increase of roughly 36%, a substantial dilution for a company with a market value near $320 million on the pre-deal count. The offering is expected to close on or about November 13, and shares are now trading about 7% below the $5.00 subscription price. That gap is the key pressure point: buyers have little incentive to pay above the deal level until the new stock is absorbed, and arbitrage-linked selling tied to the settlement is common on listing day.
Catalyst Breakdown: Profit-Taking After a 93% Surge
The retreat follows one of the most violent moves in small-cap biotech this year. On Tuesday, PepGen reported 46.5% mean splicing correction at Week 13 in the 10 mg/kg cohort of FREEDOM2-DM1 versus 6.8% for placebo, with video hand opening time improving 3.9 seconds and grip strength rising about 16.2%. Shares closed 92.9% higher at $4.61 after nearly 45 million shares changed hands, then added 14.1% on Wednesday to $5.26 before easing 4.18% on Thursday. Another leg lower is a normal mean-reversion pattern for a stock that repriced by more than 100% in three sessions, particularly one whose entire thesis now rests on a six-patient dataset with a U.S. partial clinical hold still unresolved.
Market Context and Trading Activity
The pullback is directionally consistent with a softer tape for speculative healthcare. The IBB large-cap biotech ETF is down 0.97%, the XBI equal-weight biotech ETF is down 1.63%, and DM1 competitor DYN is off 2.06%, while SRPT is down 0.62%. PepGen's decline is roughly five times the sector's, so company-specific factors dominate. Volume is far lighter than during the rally: about 360,000 shares traded in the first 20 minutes, versus roughly 1 million shares on an average day before the data and 44.5 million on Tuesday. Technically, the stock remains far above its 20- and 50-day moving averages near $2.60, but it is stalled beneath the $5.00 shelf established by the offering and remains well below its 52-week high of $7.80.
News Significance Score
The scale runs from 0, meaning no meaningful news and a normal move for the stock, to 100, meaning transformative news and an extreme, rare move. This event scores 42 out of 100. The verified news is genuinely material: a $125 million financing equal to roughly 39% of PepGen's market value is a meaningful, dilutive corporate event, and the deal price is now anchoring trading. The price move, however, is not extraordinary by this stock's standards — Friday's 8.13% decline is about 1.6 times the typical daily move of roughly 5.2%, and six sessions in the last 60 produced equal or larger swings. Strong but already-digested news combined with an unremarkable move yields a mid-range score.
What Comes Next for PEPG
The company's next scheduled catalysts are interim five-month-open-label-extension data at 5 mg/kg and 10 mg/kg safety data in January 2027, followed by 12.5 mg/kg cohort results in the first half of 2027. Investor attention will center on whether the FDA partial clinical hold, in place since March 2026 over preclinical findings, is lifted so U.S. dosing can resume ahead of any registrational path. On the financial side, the raise extends a runway that previously stretched into 2028 on $104.8 million of cash, removing near-term financing risk but resetting the valuation base. Analysts remain constructive on balance, with buy ratings and targets ranging from $6 to $16, though the small sample size, inconclusive patient-reported outcomes and four mild renal adverse events remain the principal points of debate.
Trending AI Robots
Tickeron's Trending AI Robots page curates the automated trading strategies performing best under present market conditions, drawn from a library of hundreds of AI bots covering thousands of tickers. Because bots differ widely in strategy, timeframe, performance metrics and the symbols they trade, this shortlist focuses only on those currently posting the strongest results. It is a practical starting point for traders who want to see how systematic approaches are positioned right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PEPG in -5.69% downward trend, declining for three consecutive days on November 05, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PEPG declined for three days, in 256 of 284 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
PEPG broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 59 cases where PEPG's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on PEPG as a result. In 75 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for PEPG just turned positive on November 10, 2026. Looking at past instances where PEPG's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.
PEPG moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PEPG crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +120.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where PEPG advanced for three days, in 199 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Aroon Indicator entered an Uptrend today. In 101 of 112 cases where PEPG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.431) is normal, around the industry mean (3.498). P/E Ratio (-2.470) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. PEPG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PEPG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement